Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 24, 2024

Patient Feedback for MDS: Insights and Closing Remarks

Author(s)Ryan Haumschild, PharmD, MS, MBA, James McCloskey, MD , Amer Zeidan, MD

Medical experts offer their insights and closing remarks regarding patient feedback for MDS.

Episodes in this series

EP. 1 Advances in MDS Classification and Molecular Understanding

EP. 1 Advances in MDS Classification and Molecular Understanding

EP. 2 Choosing MDS Therapies: Risk-Based Approaches

EP. 2 Choosing MDS Therapies: Risk-Based Approaches

EP. 3 Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP. 3 Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP. 4 ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP. 4 ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP. 5 Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP. 5 Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP. 6 HMA Persistence and Effectiveness in Higher Risk MDS

EP. 6 HMA Persistence and Effectiveness in Higher Risk MDS

EP. 7 Innovations and Future Directions in Higher Risk MDS Treatments

EP. 7 Innovations and Future Directions in Higher Risk MDS Treatments

EP. 8 Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP. 8 Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP. 9 Oral vs. IV HMAs: Considerations and Patient Guidance

EP. 9 Oral vs. IV HMAs: Considerations and Patient Guidance

EP. 10 Patient Feedback for MDS: Insights and Closing Remarks

EP. 10 Patient Feedback for MDS: Insights and Closing Remarks

Video content above is prompted by the following:

How do you address challenges related to medication adherence in patients with myelodysplastic syndromes (MDS) receiving oral decitabine-cedazuridine, and what strategies or tips have you found effective in promoting adherence to treatment regimens?
How can we leverage patient feedback and experiences to continuously improve MDS treatment strategies and enhance patient outcomes?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

Social Factors Shape Diabetes, Dementia Risk Across Populations

AI Reshaping Diabetes Care From Nutrition to Clinical Decisions

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD